Neumora Therapeutics (NMRA) Treasury Shares (2022 - 2026)

Neumora Therapeutics' Treasury Shares history runs 5 years deep, the most recent figure standing at $435000.0 for Q1 2026.

• On a quarterly basis, Treasury Shares rose 291.89% year-over-year to $435000.0 in Q1 2026; TTM through Mar 2026 was $435000.0, a 291.89% increase from a year earlier, with the FY2025 full-year figure at $662000.0, up 78.44% from the prior year.
• Treasury Shares rose to $435000.0 in Q1 2026 per NMRA's latest filing, from $71000.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $104.4 million in Q4 2022 and bottomed at $71000.0 in Q4 2025.
• The 5-year median for Treasury Shares is $1.5 million (2024), against an average of $28.3 million.
• Across the five-year window, Treasury Shares sank 99.2% in 2023 and soared 291.89% in 2026, its largest moves.
• Year by year, Treasury Shares stood at $104.4 million in 2022, then sank by 99.2% to $840000.0 in 2023, then plunged by 55.83% to $371000.0 in 2024, then sank by 80.86% to $71000.0 in 2025, then surged by 512.68% to $435000.0 in 2026.
• Per Business Quant, the three latest NMRA Treasury Shares figures stand at $435000.0 (Q1 2026), $71000.0 (Q4 2025), and $662000.0 (Q3 2025).